Researcher
Bart VAN WIJMEERSCH
- Keywords:Biomedical sciences (incl. biochemistry)
- Disciplines:Autoimmunity, Inflammation, Innate immunity, Transplantation immunology, Medical imaging and therapy not elsewhere classified, Neuroanatomy, Neurophysiology, Rehabilitation
Affiliations
- Rehabilitation Sciences (Faculty)
Member
From1 Sep 2018 → Today - Rehabilitation Research Center (Research group)
Member
From1 Sep 2018 → Today - Rehabilitation Sciences & Physiotherapy (Department)
Member
From1 Sep 2018 → Today - Biomedical Research Institute (Research institute)
Member
From1 Sep 2008 → Today - Immunology - Biochemistry (Research group)
Member
From1 Sep 2008 → 31 Aug 2018 - Physiology - Biochemistry - Immunology (Department)
Member
From1 Sep 2008 → 31 Aug 2018 - Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Sep 2008 → 31 Aug 2018 - Medical Basic Sciences (Division)
Member
From1 Sep 2008 → 30 Sep 2009
Projects
1 - 9 of 9
- Empirical development of a multimodal prognostication tool to guide treatment-strategy for Multiple SclerosisFrom1 Nov 2022 → TodayFunding: BOF - doctoral mandates
- Identification of multiple sclerosis-specific cytotoxic CD4 T cellsFrom1 Mar 2022 → 1 Mar 2023Funding: Industrial enterprises
- MACSiMiSE-BRAIN: Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And NeurodegenerationFrom1 Oct 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Short term changes in "Radiomic" features predict long-term treatment effectivenessFrom1 Sep 2019 → 31 Aug 2020Funding: Foreign foundations, funds with scientific view
- COGNITIVE-MOTOR INTERFERENCES DURING WALKING IN PERSONS WITH MULTIPLE SCLEROSIS: ASSESSMENT, REHABILITATION STRATEGIES AND NEURAL CORRELATESFrom1 Sep 2017 → 31 Aug 2021Funding: BOF - Doctoral projects
- Multiple sclerosis, a multidisciplinary approachFrom1 Jan 2015 → 31 Dec 2019Funding: FWO scientific research network
- T lymphocytes: from basic biology to immunotherapyFrom1 Oct 2012 → 31 Dec 2017Funding: IUAP-VII
- BOF NI project: A role for expanded CD4+CD28null T cells in patients with multiple sclerosis?From1 Jan 2012 → 31 Dec 2015Funding: BOF - Doctoral projects
- Multiple Sclerosis, a multidisciplinary appraochFrom1 Jan 2010 → 31 Dec 2014Funding: FWO scientific research network
Publications
11 - 20 of 158
- Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis(2023)
Authors: Ibrahima Diouf, Charles B. Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, et al.
Pages: 1014 - 1024 - Effect of high-efficacy therapy on the course of disability in paediatric-onset multiple sclerosis(2023)
Authors: Sifat Sharmin, Izanne Roos, Charles Malpas, Dana Horakova, Eva Havrdova, Serkan Ozakbas, Raed Alroughani, Francesco Patti, Guillermo Izquierdo, Sara Eichau Madueno, et al.
Pages: 103 - 105 - Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort(2023)
Authors: Sofie AERTS, Hamza KHAN, Deborah SEVERIJNS, Veronica POPESCU, Liesbet PEETERS, Bart VAN WIJMEERSCH
- A multi-stakeholder survey on multiple sclerosis multidisciplinary care: The situation in Belgium and lessons for the global community(2022)
Authors: L. Van Hijfte, M. Cambron, B. Capron, B. Dachy, D. Decoo, D. Dive, B. Dubois, S. El Sankari, F. London, G. Perrotta, et al.
Pages: 402 - 403 - Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis(2022)
Authors: C. Daruwalla, V. Shaygannejad, S. Ozakbas, E. K. Havrdova, R. Alroughani, F. Patti, M. Onofrj, S. Eichau, M. Girard, F. Grand'Maison, et al.
Pages: 947 - 950 - Safety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS)(2022)
Authors: X. Montalban, Bart VAN WIJMEERSCH, C. Gobbi, N. Robertson, L. Klotz, A. Achiron, A. Lee, S. Eichau, L. Vecsei, H. Benzerdjeb, et al.
Pages: 288 - Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial(2022)
Authors: Patrick Vermersch, Celia Oreja-Guevara, Aksel Siva, Bart VAN WIJMEERSCH, Heinz Wiendl, Jens Wuerfel, Regine Buffels, Karen Kadner, Thomas Kuenzel, Giancarlo Comi
Pages: 790 - 801 - Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis(2022)
Authors: M. Lefort, S. Sharmin, J. B. Andersen, S. Vukusic, R. Casey, M. Debouverie, G. Edan, J. Ciron, A. Ruet, J. De Seze, et al.
- Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in(2022)
Authors: M Pugliatti, HP Hartung, C Oreja-Guevara, C Pozzilli, L Airas, M Alkhawajah, N Grigoriadis, M Magyari, Bart VAN WIJMEERSCH, M Zakaria, et al.
- Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180](2022)
Authors: Edward DE BROUWER, Thijs BECKER, Yves Moreau, Eva Kubala Havrdova, Maria Trojano, Sara Eichau, Serkan Ozakbas, Marco Onofrj, Pierre Grammond, Jens Kuhle, et al.
Pages: 106479